由来生物
rabbit
品質水準
結合体
unconjugated
抗体製品の状態
IgG fraction of antiserum
抗体製品タイプ
primary antibodies
クローン
polyclonal
フォーム
buffered aqueous solution
分子量
antigen approximately 57 kDa
化学種の反応性
human
テクニック
microarray: suitable
western blot: 0.5 μg/mL using human HeLa cell extract
UniProtアクセッション番号
輸送温度
dry ice
保管温度
−20°C
遺伝子情報
human ... TNFRSF10A(8797)
詳細
DR4, referred to as TRAIL Receptor-1, is a novel death domain containing receptor whose ligand has been identified as TRAIL or apoptosis-inducing ligand 2 (Apo2L). It is a member of the TNF superfamily of receptors that induce apoptosis. It is expressed in most human tissues including spleen, peripheral blood leukocytes, small intestine, and thymus.
免疫原
synthetic peptide corresponding to amino acids 1-20 of the N-terminal of the mature human DR4.
アプリケーション
Anti-DR4 antibody produced in rabbit is suitable for microarray and immunoblotting at a working dilution of 1:500-1:1000 using total HeLa, K562, and Jurkat whole cell lysates. It was used as a primary antibody in the immunodetection of DR4 in cell lysate of human small cell lung carcinoma cells. It was used as a primary antibody in the immunoblot analysis of fetal and adenocarcinoma epithelial colon cells in a study.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
生物化学的／生理学的作用
DR4 induces apoptosis in a variety of human tumor cell lines, but not in normal cells and activates NF-κB.
物理的形状
PBS溶液(0.02%アジ化ナトリウム含有)。
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
10 - Combustible liquids
Lenka Kočí et al.
Cytokine, 55(1), 34-39 (2011-04-13)
The resistance of transformed epithelial cells to a detachment-induced apoptosis (anoikis) can significantly affect their susceptibility to anticancer therapy. We showed that detachment of both fetal (FHC) and adenocarcinoma (HT-29) human colon epithelial cells resulted in the activation of the
P Schneider et al.
Immunity, 7(6), 831-836 (1998-01-16)
TRAIL induces apoptosis through two closely related receptors, TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Here we show that TRAIL-R1 can associate with TRAIL-R2, suggesting that TRAIL may signal through heteroreceptor signaling complexes. Both TRAIL receptors bind the adaptor molecules FADD and
Alena Vaculova et al.
Molecular cancer, 9, 87-87 (2010-04-27)
TRAIL is considered as a promising anti-cancer agent, because of its ability to induce apoptosis in cancer but not in most normal cells. However, growing evidence exist that many cancer cells are resistant to its apoptotic effects. SCLC is a
S R Wiley et al.
Immunity, 3(6), 673-682 (1995-12-01)
A novel tumor necrosis factor (TNF) family member has been cloned and characterized. This protein, designated TNF-related apoptosis-inducing ligand (TRAIL), consists of 281 and 291 aa in the human and murine forms, respectively, which share 65% aa identity. TRAIL is
G Pan et al.
Science (New York, N.Y.), 276(5309), 111-113 (1997-04-04)
TRAIL (also known as Apo-2L) is a member of the tumor necrosis factor (TNF) ligand family that rapidly induces apoptosis in a variety of transformed cell lines. The human receptor for TRAIL was found to be an undescribed member of
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）